Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ami B Patel

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Nuclear-Cytoplasmic Transport Is a Therapeutic Target in MyelofibrosisDongqing Yan, Anthony D Pomicter, Srinivas Tantravahi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Blood Cancer Journal|June 18, 2024
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasmsAmandeep Kaur, Alexandra E Rojek, Emily Symes, et al.
Blood Cancer Discovery|May 24, 2021
SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIADongqing Yan, Anca Franzini, Anthony D Pomicter, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Nuclear-Cytoplasmic Transport Is a Therapeutic Target in MyelofibrosisDongqing Yan, Anthony D Pomicter, Srinivas Tantravahi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Blood Cancer Journal|June 18, 2024
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasmsAmandeep Kaur, Alexandra E Rojek, Emily Symes, et al.
Blood Cancer Discovery|May 24, 2021
SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIADongqing Yan, Anca Franzini, Anthony D Pomicter, et al.
Pageof 5